D008228DisordersC04.557.386.480C15.604.515.569.480C20.683.515.761.48016200.976529Lymphoma, Non-Hodgkinprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonWake Forest School of MedicineEvelynAnthonyEvelyn Y. Anthony MD36.08862300000000-80.26821099999999257Anthony, EvelynProfessorGlennLesserGlenn J. Lesser MD36.08919100000000-80.26677800000000315Lesser, GlennProfessorStephenKritchevskyStephen Kritchevsky PhD36.08884000000000-80.27016200000000903Kritchevsky, StephenProfessor29252084Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser GLeukemia & lymphomaLamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma. 2018 08; 59(8):1871-1877.Leuk Lymphoma2017-12-18T00:00:002017Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.31515574Nachmias B, Sandler V, Slyusarevsky E, Pogrebijski G, Kritchevsky S, Ben-Yehuda D, Goldschmidt N, Gatt MEAnnals of hematologyNachmias B, Sandler V, Slyusarevsky E, Pogrebijski G, Kritchevsky S, Ben-Yehuda D, Goldschmidt N, Gatt ME. Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients. Ann Hematol. 2019 Nov; 98(11):2561-2567.Ann Hematol2019-09-12T00:00:002019Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients.Internal Medicine, Gerontology & Geriatric MedicineInternal Medicine, Hematology & OncologyStevenParkSteven Park MD3224Park, StevenClinical Professor28945884Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BDAnnals of oncology : official journal of the European Society for Medical OncologyMartin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017 Nov 01; 28(11):2806-2812.Ann Oncol2017-11-01T00:00:002017A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).32270047Au KM, Wang AZ, Park SIScience advancesAu KM, Wang AZ, Park SI. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma. Sci Adv. 2020 Apr; 6(14):eaaz9798.Sci Adv2020-04-01T00:00:002020Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.31429028Park SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania BTargeted oncologyPark SI, Lin CP, Ren N, Angus SP, Dittmer DP, Foote M, Parton T, Bhatt AP, Fedoriw YD, Roth DP, Cann ML, Johnson GL, Damania B. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Target Oncol. 2019 Oct; 14(5):563-575.Target Oncol2019-10-01T00:00:002019Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.true1ProfessorProfessortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1Clinical Associate ProfessorClinical Associate Professortrue1ProfessorProfessorRakheeVaidyaRakhee Vaidya MBBS36.08919100000000-80.266778000000001641Vaidya, RakheeClinical Associate ProfessorDiagnostic Radiology1.463740.033045316research area of0.7624750.041051142subject area for